|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 600 Massachusetts Ave, NW |
Address2 | SUITE 300 |
City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Washington |
State | DC |
Zip Code | 20001 |
Country | USA |
|
5. Senate ID# 15920-12
|
||||||||
|
6. House ID# 314640000
|
TYPE OF REPORT | 8. Year | 2022 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Jessica Friend |
Date | 10/20/2022 4:43:09 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 5402 - FY 2022 Labor, HHS, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022
H.R. 5305 Extending Government Funding and Delivering Emergency Assistance Act
H.R. 2471 Consolidated Appropriations Act, FY2022
-Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
-Strategic National Stockpile (SNS) Funding and Oversight
-Funding for FDA e-labeling rule implementation
-Patient access to Part B medicines during the COVID-19 public health emergency
-Issues related to 340B program oversight
-Support for increased investments to address antimicrobial resistance.
-Deficit reduction, reconciliation
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Matthew |
Sulkala |
|
|
|
Catherine |
Phillips |
|
|
|
Elise |
Conner |
|
|
|
Vanessa |
Gannon |
|
|
|
Thomas |
Stoll |
|
|
|
Ravi |
Upadhyay |
|
|
|
Jill |
Shotzberger |
|
|
|
David |
Cooling |
|
|
|
Caleb |
Graff |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S. 4417 Patent Trial and Appeal Board Reform Act
S. 4734 Patent Eligibility Restoration Act
S. 1435 - Affordable Prescriptions for Patients Act of 2021
H.R. 2873 Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
H.R. 2884 Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
-Intellectual property and process patent issues
-Patent litigation reforms
-PTAB and IPR processes
-Section 101 Reform
-Domestic and international compulsory licensing issues
-March-in Rights
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR), Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R.8152 - American Data Privacy and Protection Act
-Issues relating to privacy and securing the data of and personal health information of patients/consumers
-Issues relating to medical research data
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Jill |
Shotzberger |
|
|
|
Thomas |
Stoll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R.5260 - Reduced Costs and Continued Cures Act
H.R. 5125 - the Strengthening Innovation in Medicare and Medicaid Act
H.R. 5376 - Build Back Better Act
-Issues related to Medicare and Medicaid coverage and reimbursement
-Issues related to the 340B Drug Discount Program
-Issues related to drug pricing
-Medicare reimbursement for biosimilars
-Issues related to CMMI
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Matthew |
Sulkala |
|
|
|
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Vanessa |
Gannon |
|
|
|
Jill |
Shotzberger |
|
|
|
Ravi |
Upadhyay |
|
|
|
Caleb |
Graff |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 1304, the American Innovation and R&D Competitiveness Act and
S. 749 American Innovation and Jobs Act
S.1260 - United States Innovation and Competition Act of 2021
-Issues related to R&D tax deductions and expense amortization
-Issues related to international taxation, including foreign-derived intangible income and interest deductions
-Issues related to supply chain incentives
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
|
Catherine |
Phillips |
|
|
|
Matthew |
Sulkala |
|
|
|
Ravi |
Upadhyay |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R. 3788, the Protecting American Innovation Act
H.R. 3811, the Trade Related Intellectual Property Protection Act
H.R. 7185, the Federal Contracting for Peace and Security Act
-Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver
-Issues related to compulsory licensing of foriegn patents
-Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
H.R. 2471 Consolidated Appropriations Act, FY2022
S.2076/H.R. 3932 PASTEUR Act
H.R.7667 - Food and Drug Amendments of 2022
S.4348 - FDASLA Act of 2022
H.R.6963 - Accelerated Approval Integrity Act of 2022
H.R.6996 - Accelerating Access for Patients Act of 2022
H.R. 2565 / S.2952 the FDA Modernization Act
H.R. 6972 - Give Kids a Chance Act
H.R. 1730 - STAT Act
H.R. 7032 - Increasing Transparency in Generic Drug Applications Act
H.R. 5030/S. 2706 - DIVERSE Trials Act
H.R. 6584 - DEPICT Act
H.R.3085 - ENACT Act of 2021
-Issues related to public health protection including influenza development and preparedness
-Issues related to antimicrobial and antiviral research and product development
-Issues related to novel coronavirus and COVID-19 research and product development
-Issues related to drug development including PDUFA and Cures 2.0
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Vanessa |
Gannon |
|
|
|
Elise |
Conner |
|
|
|
David |
Burt |
|
|
|
Catherine |
Phillips |
|
|
|
Dan |
Neves |
|
|
|
David |
Cooling |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 2163/S. 464 - Safe Step Act
H.R. 5376 - Build Back Better Act
H.R. 5801 - Help Ensure Lower Patient (HELP) Copays Act
-Drug pricing issues
-Prescription Drug User Fee Act reauthorization
-Issues related to prescription drug value
-Issues related to the 340B Drug Discount Program
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Elise |
Conner |
|
|
|
Catherine |
Phillips |
|
|
|
Vanessa |
Gannon |
|
|
|
Ravi |
Upadhyay |
|
|
|
Jill |
Shotzberger |
|
|
|
David |
Cooling |
|
|
|
Matthew |
Sulkala |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MAN
16. Specific lobbying issues
S.3401 - Safe Drug Act
H.R. 7121, Protecting our Pharmaceutical Supply Chain from China Act of 2022
S.3509 - Creating Efficiency in Foreign Facility Inspections Act
-Issues related to pharmaceutical supply chains
-Issues related to reporting on location of origin of pharmaceutical products
-Issues related to drug shortages
-Issues related to pharmaceutical manufacturing
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thomas |
Stoll |
|
|
|
Dan |
Neves |
|
|
|
Jill |
Shotzberger |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
-Issues relating to limits and restrictions on the immigration of high skilled workers
-Issues relating to the immigration of medical researchers
17. House(s) of Congress and Federal agencies Check if None
Homeland Security - Dept of (DHS), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Burt |
|
|
|
Thomas |
Stoll |
|
|
|
Matt |
Sulkala |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |